

06/07/00
jc813 U.S. PTO

06-08-JD

A

Please type a plus sign (+) inside this box ☐

Attorney Docket P1759R1

1c580 U.S. PTO

09/589395

06/07/00

CERTIFICATION UNDER 37 CFR 1.10

EK517180296US: Express-Mail Number

June 7, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Diane L. Marschang
Diane L. Marschang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi Ashkenazi, San Mateo, California
Mark Benyunes, San Francisco, California
Ralph Schwall, Pacifica, California

Title: **Apo-2L Receptor Agonist and CPT-11 Synergism**

1. Type of Application

- [] This application is for an original, non-provisional application.
- [X] This is a non-provisional application claiming priority to provisional application no. 60/138,240, filed June 9, 1999, the entire disclosure of which is hereby incorporated by reference.
- [] This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number Serial No., filed Filing Date, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

68 pages of specification
2 pages of claims
1 page(s) of abstract
2 sheet(s) of drawings
[] formal [X] informal

09589395-060700

X An executed declaration of the inventors [X] is enclosed ☐ will follow.

— A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

— A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

5. Amendments (for continuation and divisional applications)

X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.

____ The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

_____ Cancel in this application original claims __ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

_____ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$690.00
Total Claims	18	- 20 =	0	X \$18.00	\$0.00
Independent Claims	4	- 3 =	1	X \$78.00	\$78.00
Multiple dependent claim(s), if any				+ \$260.00	\$0.00
Filing Fee Calculation					\$768.00

7. Method of Payment of Fees

X The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$768.00.00 **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

X The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- _____ A copy of the petition for extension of time in the **prior** application is attached.

002090-566890

11. Correspondence Address:

X Address all future communications to:

GENENTECH, INC.
Attn: Diane L. Marschang
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5416

Respectfully submitted,
GENENTECH, INC.

Date: June 7, 2000

By: *Diane L. Marschang*
Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

004090-9628960